Background/aims: Locally advanced (T4 per American Joint Committee on Cancer (AJCC) 8th edition) periocular basal cell carcinoma (BCC) can lead to loss of the eye. We report the neoadjuvant use of vismodegib followed by surgery in patients with such lesions with eye preservation as primary goal.
Methods: This retrospective interventional study includes all patients with a T4 periocular BCC (per 8th edition AJCC for eyelid carcinoma) treated by the senior author between 2013 and 2017 with neoadjuvant vismodegib prior to definitive surgery.
Results: Eight patients had a T4 tumour. Six patients presented with recurrent disease. Indications for neoadjuvant treatment were an unresectable tumour in one patient, an attempt to avoid an orbital exenteration in six patients and an attempt to avoid disfiguring facial surgery in one patient. Patients were treated for a median of 14 months (range: 4-36 months). All patients underwent an eye-sparing surgery following neoadjuvant vismodegib and all final surgical margins were negative for tumour. Five patients had a complete response to vismodegib with no microscopic residual BCC found during surgery; three patients had a significant partial response with residual tumour found on pathology. At last follow-up, a mean of 18 (range: 6-43) months after surgery, all patients were off-vismodegib and alive without evidence of disease.
Conclusions: Neoadjuvant vismodegib for locally advanced (T4) periocular BCC enabled an eye-sparing surgery in all patients in our cohort. Prolonged treatment was well tolerated by most patients. Over half of patients achieved a complete response with no residual microscopic disease. Careful long-term follow-up is needed to confirm long-term disease-free survival.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bjophthalmol-2018-312277 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Therapeutic Approaches for Advanced Basal Cell Carcinoma: A Comprehensive Review.
Cancers (Basel)
December 2024
Department of Dermatology and Allergology, Paracelsus Medical University, Muellner Hauptstraße 48, 5020 Salzburg, Austria.
Basal cell carcinoma (BCC) accounts for 80% of skin cancer cases. Although mostly curable by simple excision, the treatment of advanced disease can be challenging, as curative surgery or radiotherapy may not always be feasible. The scope of this review is to summarize current knowledge on molecular mechanisms in BCC pathogenesis, to elaborate on the definition of advanced/difficult-to-treat BCC, and to outline systemic treatment options.
View Article and Find Full Text PDFOral Hedgehog Inhibitor, Vismodegib, for Locally Advanced Periorbital and Orbital Basal Cell Carcinoma: A Report by the American Academy of Ophthalmology.
Ophthalmology
November 2024
Department of Ophthalmology, Vanderbilt University School of Medicine, Nashville, Tennessee.
Article Synopsis
- The review analyzed the effectiveness and safety of oral vismodegib (Erivedge) for treating locally advanced basal cell carcinoma (BCC) in the orbit and periorbital area, finding 16 relevant studies out of 60 identified.
- Results showed high response rates, with some studies reporting up to 100% patient response and significant tumor volume reduction, which helped preserve the eye in most cases, but many patients still required surgery for recurrences.
- Common side effects, experienced by nearly all patients, included muscle cramps, alopecia, and fatigue, leading to therapy discontinuation in some; critical mutations in tumors were also noted, indicating potential resistance to future treatments.
Vismodegib as an adjuvant treatment for periorbital basal cell carcinoma: a case report and review of literature.
Ann Transl Med
June 2024
Jones Eye Institute, Department of Ophthalmology, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Article Synopsis
- * A case study of a 50-year-old man with recurrent periorbital BCC involved Mohs micrographic surgery and subsequent treatment with oral vismodegib, resulting in significant tumor shrinkage.
- * Combining neoadjuvant vismodegib with surgical methods like Mohs micrographic surgery shows promising results for treating periorbital BCC, improving both clinical and aesthetic outcomes.
Personalized treatment concepts in extraocular cancer.
Adv Ophthalmol Pract Res
March 2024
Department of Ophthalmology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Kerpener Straße, Cologne, Germany.
Article Synopsis
- The periocular skin is highly susceptible to both benign and malignant tumors, with malignancies in this area being more aggressive and harder to treat compared to other skin regions.
- Recent advancements in immunotherapy have enabled the immune system to effectively target and destroy cancer cells, particularly benefiting the treatment of periocular tumors.
- The choice of treatment for periocular skin cancer should be individualized based on tumor type, size, and genetic factors, and may involve a combination of chemotherapy and immunotherapy options.
A Multidisciplinary approach to metastatic giant basal cell carcinoma-A case report.
JPRAS Open
June 2024
Turku University Hospital, Department of Plastic and General Surgery, Finland.
We present a case of a 49-year-old man with a giant basal cell carcinoma of the back, with metastases in the lungs, liver, mediastinum and both adrenal glands. Neoadjuvant vismodegib was administered, after which wide local resection of the tumour was performed. There have been no signs of local recurrence.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!